Home / News & Updates

News & Updates

Case breakthroughs, oncology advances, and resources from Beijing Arion Cancer Hospital — UPMC-affiliated tertiary cancer center.

Case Breakthrough Volume 30 — primary breast small-cell neuroendocrine carcinoma after seven lines of therapy and the transition to palliative care
Case Breakthrough October 4, 2026

Progression After Seven Lines of Therapy — MDT Collaboration in High-Risk Primary Breast SCNEC and the Transition to Palliative Care

A 42-year-old woman with high-grade primary breast small-cell neuroendocrine carcinoma progressed through seven lines of advanced therapy. When her physiological reserve fell below the safety threshold for any further cytotoxic or targeted therapy, the Arion MDT shifted the goal of care from tumor control to palliative symptom control — dynamically adjusting treatment goals across the disease course.

Read More →
Case Breakthrough Volume 29 — MDT-guided LM101 autologous CD19 CAR-T for a 68-year-old with high-risk CD5-positive diffuse large B-cell lymphoma
Case Breakthrough October 2, 2026

From Multi-Line Resistance to Complete Metabolic Response: MDT-Guided LM101 CD19 CAR-T in a 68-Year-Old with High-Risk CD5+ DLBCL

A 68-year-old woman with stage IVB high-risk CD5-positive GCB DLBCL progressed after first-line immunochemotherapy and second-line chemo plus a CD20/CD3 bispecific antibody. MDT review of three options led to the LM101 autologous CD19 CAR-T trial — one-month PET-CT showed complete metabolic response of the abdominal nodes and PR of a chest-wall lesion, with no CRS or ICANS.

Read More →
Case Breakthrough Volume 28 — MDT-guided multi-line treatment of advanced HER2-mutant lung adenocarcinoma, from ADC resistance to renewed immunotherapy benefit
Case Breakthrough October 2, 2026

From ADC Resistance to Renewed Immunotherapy Benefit: MDT-Guided Multi-Line Treatment Decisions in Advanced HER2-Mutant Lung Adenocarcinoma

A 47-year-old man with stage IVB lung adenocarcinoma and an ERBB2 p.Y772_A775dup mutation progressed through chemo-immunotherapy, trastuzumab deruxtecan, pyrotinib and zongertinib. A re-biopsy after ADC resistance revealed INI1 loss, MYC amplification and a PD-L1 rise to 75% — redirecting treatment to ivonescimab plus chemotherapy with a partial response.

Read More →
Case Breakthrough Volume 27 — detection of the rare pathogen Nocardia otitidiscaviarum in a lung cancer patient with worsening interstitial lung disease
Case Breakthrough September 24, 2026

Worsening ILD with New Consolidation in a Lung Cancer Patient: Detection of Nocardia otitidiscaviarum, a Rare Pathogen

A 72-year-old man with stage III right main bronchus squamous cell carcinoma on steroids for worsening interstitial lung disease developed fever with new right upper lobe consolidation. A sputum smear showing Gram-positive branching bacilli prompted modified acid-fast staining and a repeat deep sputum sample — and culture of Nocardia otitidiscaviarum.

Read More →
Case Breakthrough Volume 26 — fecal microbiota transplantation for refractory diarrhea in a post-gastrectomy gastric cancer patient with cirrhosis
Case Breakthrough September 24, 2026

FMT Breaks the Deadlock of Refractory Diarrhea in a Patient with Multiple Comorbidities: MDT Decision for a Post-Gastrectomy Gastric Cancer Patient with Cirrhosis

A 61-year-old man who had undergone subtotal gastrectomy for gastric cancer, with 20 years of chronic hepatitis B and over 10 years of cirrhosis, endured refractory diarrhea for 3 years and 9 months. After multi-line conventional therapy failed, the MDT used fecal microbiota transplantation (FMT) to rebuild his gut microbiota.

Read More →
Case Breakthrough Volume 22 — MDT resolves refractory chylothorax in follicular lymphoma with thoracoscopic thoracic duct ligation
Case Breakthrough September 22, 2026

Lymphoma Meets Refractory Chylothorax: How the MDT Broke the Dilemma Between Systemic Therapy and Surgical Intervention

A 51-year-old woman with stage IVB, high-tumour-burden follicular lymphoma responded well to obinutuzumab-based immunochemotherapy — yet developed chylothorax draining about 800 ml a day that repeated thoracentesis could not cure. MDT decision-making ended the cycle with thoracoscopic thoracic duct ligation, curing the chylothorax and allowing the lymphoma to reach complete remission.

Read More →
Case Breakthrough Volume 21 — ultrasound-guided uterine biopsy reveals primary uterine lymphoma masquerading as ovarian cancer
Case Breakthrough September 20, 2026

CA125 Surge with Widespread Metastasis Mimicking Ovarian Cancer: Why Switching the Biopsy Target to the Uterus Revealed the True Culprit

A 78-year-old woman with a CA125 of 538 U/mL and synchronous uterine and bilateral adnexal masses was initially thought to have metastatic ovarian cancer. Multimodal ultrasound redirected the biopsy from the adnexa to the uterus — revealing primary diffuse large B-cell lymphoma, and a complete metabolic response to polatuzumab vedotin plus rituximab and mini-CHP.

Read More →
dMMR endometrial cancer with brain metastases — ADC plus immunotherapy rescue — Case Breakthrough Vol. 18
Case Breakthrough July 9, 2026

Widespread Metastases, Repeated Brain Progression — ADC Combined with Immunotherapy Reverses Late-Stage dMMR Endometrial Cancer Crisis

51-year-old female with dedifferentiated dMMR endometrial carcinoma (IIIB–IVB). Post-op widespread mets + brain mets with tentorial herniation. First-line chemo-immuno + WBRT achieved PR. Upon intracranial progression, sacituzumab govitecan + pembrolizumab with individualized dosing (5→4 mg/kg) and single-dose bevacizumab for edema control delivered 13+ months of stable disease — a >4× extension over GPA-predicted survival. Commentary by Prof. Wu Ming (PUMCH) & Prof. Sun Min (UPMC).

Read More →
89-year-old woman with three primary cancers receiving precision radiotherapy — Case Breakthrough Vol. 17
Case Breakthrough July 9, 2026

Three Cancers at Age 89: When Targeted & Immunotherapy Both Fail — Precision RT Restores Ambulatory Function and Delivers High-Quality Survival

An 89-year-old female with colon cancer, bladder cancer, and recurrent malignant peripheral nerve sheath tumor (15 cm) experienced severe toxicity from both anlotinib (hematuria, hydronephrosis) and tislelizumab (fever, AKI). Dual-site SBRT achieved significant tumor shrinkage, restored independent walking, with only Grade 1 toxicity. Expert commentary by Prof. Cai Yong (Peking University Cancer Hospital).

Read More →
Prof. Xiao Yu from Peking University Third Hospital, Dr. Jiang Bin from Arion, and Prof. Sun Min from UPMC on two-stage hepatectomy for diffuse colorectal liver metastases — Case Breakthrough Vol. 16
Case Breakthrough July 9, 2026

Breaking Through Palliative Limits: Two-Stage Hepatectomy with Portal Vein Ligation Transforms Unresectable Colorectal Liver Metastases into a Curative Opportunity

60-year-old man with sigmoid colon cancer (pT4aN1M1) and diffuse whole-liver mets (>10 lesions). FOLFOX+cetuximab achieved CEA 191→3.12 ng/mL but FLR insufficient for one-stage resection. Arion MDT selected TSH-PVL over ALPPS: Stage-I laparoscopic colectomy + left liver mets clearance (9 lesions) + right PVL → HAIC+FOLFOX interval → Stage-II right hemihepatectomy planned. Expert commentary by Profs. Xiao Yu (PKU Third Hospital) & Sun Min (UPMC).

Read More →
Prof. Sun Min from UPMC and Prof. Bai Li from PLA General Hospital on rare intrasinusoidal breast cancer liver metastasis reversed by T-DXd — Case Breakthrough Vol. 15
Case Breakthrough July 9, 2026

Breaking the End-Stage Verdict: CDK4/6i Rapid Resistance Near Death — Rare Sinusoidal Metastasis Identified by MDT, ADC Therapy Reverses Visceral Crisis

46F with HR+/HER2-low metastatic breast cancer developed rapid progression on ribociclib (PFS only 13 months), presenting as visceral crisis: acute liver failure (AST 320 U/L), severe hypoxemia (SpO&sub2; 81%), and portal vein flow reversal. Arion's MDT diagnosed rare diffuse intrasinusoidal hepatic metastasis causing hepatopulmonary syndrome through pathophysiological reasoning — confirmed by liver biopsy. T-DXd rescue normalized portal flow in 2 weeks, achieved PR after 3 cycles. Expert commentary by Profs. Sun Min (UPMC) & Bai Li (PLA General Hospital).

Read More →
Prof. Yu Chunhua from PUMCH and Prof. Zhou Wan from Beijing Arion Cancer Hospital on high-risk anesthesia enabling thyroid cancer surgery in a patient with complex congenital heart disease — Case Breakthrough Vol. 14
Case Breakthrough July 9, 2026

Defying Surgical Contraindication: High-Stakes Anesthesia Management Enables Curative Thyroid Cancer Resection in a Patient with Complex Congenital Heart Disease

A 46-year-old woman with papillary thyroid cancer was rejected by multiple hospitals due to complex congenital heart disease (single atrium, single ventricle, transposition of great arteries, severe pulmonary stenosis, SpO2 77-81%). Arion's anesthesia-led MDT team delivered precision perioperative management — 6-pillar strategy, slow-sequence induction, protective lung ventilation, continuous vasoactive support — achieving safe total thyroidectomy with neck dissection in 3h03m, extubated in OR, discharged on Day 2. Expert commentary by Prof. Yu Chunhua (PUMCH).

Read More →
Prof. Xue Weicheng from Peking University Cancer Hospital and Prof. Zhang Bo from Beijing Arion Cancer Hospital on Primary Mediastinal Large B-Cell Lymphoma — Case Breakthrough Vol. 13
Case Breakthrough July 9, 2026

Seemingly Dangerous, Yet Highly Curable: A Clinical Guide to Primary Mediastinal Large B-Cell Lymphoma — The Disease That Straddles Two Worlds

A 45-year-old woman with an anterior mediastinal mass was diagnosed with PMBCL — a unique lymphoma that bridges Hodgkin and non-Hodgkin classifications. Complete IHC profiling (CD20+, CD30+, MUM1+, Bcl-2+, high Ki67) reveals its hybrid biology. With 5-year survival of 80–90%, accurate diagnosis unlocks highly effective immunochemotherapy and emerging immunotherapies. Expert commentary by Prof. Xue Weicheng (Peking University Cancer Hospital).

Read More →
Prof. Zhang Wei from PUMCH and Prof. Wang Wenyan from Arion on refractory DLBCL treated with bispecific antibody after dual CAR-T failure — Case Breakthrough Vol. 12
Case Breakthrough July 9, 2026

When Two CAR-T Therapies Fail: How Sequential Bispecific Antibody Rescues Refractory Diffuse Large B-Cell Lymphoma

A 57-year-old woman with multi-refractory DLBCL failed two CAR-T cell therapies (CD20-targeted, then novel CD19/PD1/CD28 LM101) due to T-cell exhaustion and poor expansion. MDT-guided sequential glofitamab (CD20/CD3 bispecific antibody) achieved disease control with normalized blood counts, resolved lymphadenopathy, and no Grade ≥ 2 toxicity. Expert commentary by Prof. Zhang Wei (PUMCH).

Read More →
Prof. Bai Li, Prof. Yang Xuhui, and Prof. Han Chun on cholangiocarcinoma liver metastasis treated with HAIC combined with immunotherapy — Case Breakthrough Vol. 11
Case Breakthrough July 9, 2026

Rapid Recurrence 4 Months Post-Surgery and No Options Left? HAIC Combined with Immunotherapy Achieves a Breakthrough in Desperate Circumstances

A 58-year-old man with cholangiocarcinoma developed liver metastasis just 4 months after Whipple procedure (T3N0M0). With PD-L1 CPS=65 and KRAS G12R mutation, MDT-guided hepatic arterial infusion chemotherapy (HAIC) with nal-IRI + tislelizumab achieved stable disease and PFS exceeding 1 year — navigating a critical "mixed response" at cycle 5. Expert commentary by Prof. Bai Li (PLA General Hospital).

Read More →
Prof. Wu Ming and Prof. Li Liping on the value of ultrasound-guided biopsy in distinguishing cervical lymphoma from cervical cancer — Case Breakthrough Vol. 10
Case Breakthrough July 8, 2026

Cervical Mass ≠ Cervical Cancer: How Ultrasound-Guided Biopsy Revealed a Rare Lymphoma in a 53-Year-Old Woman

A 53-year-old woman with a 7-cm cervical mass suspected as cancer — but HPV-negative and TCT ASC-US — underwent MDT evaluation with ultrasound re-assessment showing diffuse hypoechoic texture with preserved cervical canal. Transvaginal ultrasound-guided biopsy diagnosed non-Hodgkin DLBCL, NOS, GCB type. She achieved clinical cure with 6 months of rituximab-based therapy. Expert commentary by Prof. Wu Ming (Peking Union Medical College Hospital).

Read More →
Prof. Qiao Zhiyu and Prof. Luo Yong on high-risk ureteral cancer with multiple arterial aneurysms — Case Breakthrough Vol. 9
Case Breakthrough July 8, 2026

Rejected by 5 Hospitals: How MDT Defuses Two Lethal Threats — High-Risk Ureteral Cancer with Thoracic, Abdominal, and Iliac Aneurysms

A 65-year-old woman with high-risk ureteral cancer complicated by severe thoracic aortic aneurysm (ulcerative transmural type at the arch), abdominal/iliac aneurysms, CAD, and PE — turned away by five hospitals — achieves R0 laparoscopic radical resection with only 20mL blood loss through Arion's specialized cardiovascular-oncology MDT. Now on adjuvant disitamab vedotin + toripalimab. Expert commentary by Prof. Qiao Zhiyu (Beijing Anzhen Hospital).

Read More →
Prof. Xiao Yu and Prof. Jiang Bin on MSI-H duodenal mixed carcinoma dual immunotherapy conversion and MDT radical resection — Case Breakthrough Vol. 8
Case Breakthrough July 8, 2026

When Pathology Surprises Everyone: How Dual Immunotherapy Conversion + MDT-Guided Radical Pancreaticoduodenectomy Achieved R0 Resection in MSI-H Duodenal Mixed Carcinoma

A 57-year-old woman with locally advanced MSI-H duodenal adenocarcinoma, complete obstruction, jaundice, and severe malnutrition undergoes neoadjuvant dual immunotherapy (ipilimumab + nivolumab) achieving CEA reduction from 245 to 68 ng/ml, followed by radical pancreaticoduodenectomy (R0) — only to reveal postoperative mixed neuroendocrine-non-neuroendocrine carcinoma. Now on adjuvant EP + immune maintenance. Expert commentary by Prof. Xiao Yu (Peking University Third Hospital).

Read More →
Prof. Cai Yong on MDT-guided IMRT + Traditional Chinese Medicine for 82-year-old gastric cancer patient on dialysis — Case Breakthrough Vol. 7
Case Breakthrough July 8, 2026

When Surgery Is Not an Option: How MDT-Guided IMRT + Traditional Chinese Medicine Achieved Over 1-Year Stable Disease in an 82-Year-Old Gastric Cancer Patient on Dialysis

An 82-year-old man with locally advanced gastric adenocarcinoma, chronic renal failure on dialysis, and post-coronary stent history achieves partial response and over 1-year stable disease through MDT-guided IMRT (45Gy/25 fractions) combined with individualized Traditional Chinese Medicine — without surgery, chemotherapy, or a single Grade 3 adverse event. Expert commentary by Prof. Cai Yong (Peking University Cancer Hospital).

Read More →
Prof. Sun Min and Prof. Pan Yong on AKT1-mutant advanced breast cancer precision therapy with Capivasertib — Case Breakthrough Vol. 6
Case Breakthrough July 7, 2026

From CDK4/6 to ADC to AKT Inhibitor: How Precision Oncology Breaks Through Multi-Line Resistance in HR+/HER2- Advanced Breast Cancer

A 42-year-old woman with HR+/HER2- advanced breast cancer, resistant after CDK4/6 inhibitor, HDAC inhibitor, chemotherapy, and ADC therapy, achieves partial response through AKT inhibitor (Capivasertib) + fulvestrant guided by AKT1 p.E17K mutation — with MDT-managed Grade 3 rash that never stopped treatment. Expert commentary by Prof. Sun Min (UPMC).

Read More →
Prof. Zhang Junting and Prof. Hong Ganlin on adult primary intracranial sarcoma DICER1-mutant case — Case Breakthrough Vol. 5
Case Breakthrough July 7, 2026

When No Guidelines Exist: How MDT Creates a Treatment Path for Extremely Rare Adult Primary Intracranial Sarcoma, DICER1-Mutant

A 23-year-old man with a newly defined WHO entity (2021) — primary intracranial sarcoma, DICER1-mutant (Grade 4), initially misdiagnosed as CNS lymphoma — achieves gross total resection (GTR) followed by ICE chemotherapy and concurrent radiation, with 5 cycles completed and full functional preservation. With expert commentary from Prof. Zhang Junting (Beijing Tiantan Hospital).

Read More →
Prof. Zhang Shucai and Prof. Zhang Min on high tumor burden ES-SCLC quadruplet therapy — Case Breakthrough Vol. 4
Case Breakthrough July 7, 2026

When Every Organ Is Under Attack: Quadruplet Therapy + Staged Radiation Achieves 7+ Month PFS in High Tumor Burden ES-SCLC

A 67-year-old woman with extensive-stage small cell lung cancer and metastases to the brain, spleen, liver, and lymph nodes achieves 7+ month PFS through quadruplet therapy (etoposide + carboplatin + durvalumab + anlotinib), staged precision radiation, and lurbinectedin + durvalumab maintenance. With expert commentary from Prof. Zhang Shucai (Beijing Chest Hospital).

Read More →
Prof. Wu Ming and Prof. Li Ya from Peking Union Medical College Hospital collaborating with Arion on complex gynecologic tumor case — Case Breakthrough Vol. 3
Case Breakthrough July 7, 2026

When Pathology Changes Three Times and Pulmonary Embolism Strikes: How MDT Achieves a Pathologic Complete Response in Dual Primary Gynecologic Cancer

A 68-year-old woman with dual primary cancers—endometrial clear cell carcinoma and undifferentiated ovarian sarcoma—navigates three pathology shifts, a life-threatening pulmonary embolism, and achieves pCR through neoadjuvant immunotherapy and MDT surgery. With expert commentary from Prof. Wu Ming (Peking Union Medical College Hospital).

Read More →

Medical Resources

Useful information for international patients considering cancer treatment in China.

📄

Understanding Cancer Staging

A guide to TNM staging, pathology reports, and what your diagnosis means for treatment options and prognosis.

Coming soon →
📖

Preparing for Your MDT Consultation

What to bring to your first MDT consultation at Arion: medical records, imaging, pathology slides, list of questions, and more.

Remote consultation guide →
✈

Travel Guide for Cancer Patients

Practical tips for international travel during cancer treatment: what to pack, medication management, and staying comfortable.

Visa & travel guide →

Stay Informed About Advances in Cancer Care

Contact our team to learn more about the latest oncology developments and treatment options at Beijing Arion Cancer Hospital.

Book a Consultation Chat on WhatsApp